Neok Bio is a biotechnology company focused on developing innovative bispecific antibody‑drug conjugates (ADCs) for cancer treatment. Leveraging a dual‑targeting approach, the firm aims to improve safety and efficacy of ADCs against solid tumours with high unmet medical need. Backed by ABL Bio, Neok Bio’s pipeline includes several differentiated bispecific ADC candidates, and the company positions itself at the forefront of precision oncology therapeutics.
No recent news for this company.